Share on StockTwits

Shares of TG Therapeutics (NASDAQ:TGTX) were the recipient of a large growth in short interest during the month of July. As of July 31st, there was short interest totalling 2,896,549 shares, a growth of 39.4% from the July 15th total of 2,077,751 shares, Analyst RN reports. Currently, 10.2% of the company’s shares are short sold. Based on an average daily volume of 533,819 shares, the days-to-cover ratio is presently 5.4 days.

TGTX has been the subject of a number of recent research reports. Analysts at Roth Capital raised their price target on shares of TG Therapeutics to $25.00 in a research note on Tuesday, July 22nd. They now have a “buy” rating on the stock. Separately, analysts at Brean Capital raised their price target on shares of TG Therapeutics from $13.00 to $19.00 in a research note on Tuesday, July 22nd. They now have a “buy” rating on the stock. Finally, analysts at MLV & Co
raised their price target on shares of TG Therapeutics from $10.00 to $16.00 in a research note on Wednesday, July 2nd. They now have a “buy” rating on the stock.

TG Therapeutics (NASDAQ:TGTX) opened at 7.55 on Thursday. TG Therapeutics has a 52-week low of $2.97 and a 52-week high of $11.56. The stock’s 50-day moving average is $9.01 and its 200-day moving average is $6.9. The company’s market cap is $287.8 million.

TG Therapeutics (NASDAQ:TGTX) last posted its earnings data on Tuesday, July 22nd. The company reported ($0.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by $0.08. Analysts expect that TG Therapeutics will post $-1.28 EPS for the current fiscal year.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.